340B Podcast Series, Episode 4: HRSA 340B Rebate Model Pilot Program Version 2 Overview with Clay Willis
IntegriChain's Clay Willis unpacks the 340B Rebate Model Pilot Program Version 2 (released July 31, 2026), covering the key requirements, timeline, and data provisions manufacturers need to know before the January 1, 2027 effective date, as well as his take on the limitations for the manufacturers and drugs allowed to participate in the program.
This episode dives into what the 340B Rebate Model Pilot Program actually solves for manufacturers, and what questions remain unanswered.
About this Episode
HRSA released Version 2 of its 340B Rebate Model Pilot Program on July 31, 2026, exactly one year after Version 1. Clay walks through the roughly 20 requirements manufacturers must meet, the key dates leading up to the January 1, 2027 effective date, and how Version 2 compares to Version 1. He also explains why, in his view, the rebate model does little for manufacturers beyond MFP deduplication.
Episode Highlights
- The HRSA 340B rebate model pilot program only applies to 2026 and 2027 MFP-selected drugs: 25 drugs from 13 manufacturers, making up about 5% of 340B covered entity purchases.
- Key dates: manufacturer plans are due August 24, HRSA approves or denies plans by September 24, and manufacturers must notify covered entities by October 2, 2026, 90 days before the effective date.
- Rebates must equal WAC minus the 340B price, be paid at the unit level, and be paid or denied within 10 days.
- Manufacturers can only deny rebates for MFP duplicate discounts or duplicate claims. Eligibility, diversion, Medicaid duplicate discounts, and a perceived lack of WAC purchases are off the table.
- Clay’s take: Version 2 is even more limited than Version 1, since most manufacturers already collect 340B claims through their own policies and many have cut WAC prices to near MFP.
FAQs
What is the HRSA 340B rebate model pilot program?
It’s an HRSA program that lets eligible manufacturers provide 340B pricing through rebates instead of upfront discounts on MFP-selected drugs. Participation is optional, and Version 2 runs for all of 2027.
Which drugs are eligible for the HRSA 340B rebate model?
Only MFP-selected drugs for 2026 and 2027 qualify: 25 drugs from 13 manufacturers.
When does the 340B rebate model pilot program start?
Version 2 takes effect January 1, 2027, and runs for one year. HRSA plans to release an evaluation of the pilot on April 30, 2028.
Catch Up on the 340B Podcast Series
New to the series? Episode 3 breaks down HRSA’s 2025 340B purchase data and what’s driving 340B growth.